Avity Investment Management Inc. Trims Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Avity Investment Management Inc. reduced its stake in Thermo Fisher Scientific Inc. by 16.2%, now holding 39,205 shares valued at approximately $15.9 million.
• Thermo Fisher Scientific reported earnings of $5.36 per share in its last quarter, exceeding analysts' expectations of $5.22, with revenue increasing by 2.9% year-over-year.
• The company declared a quarterly dividend of $0.43, with an annualized yield of 0.4%, demonstrating a dividend payout ratio of 9.95%.

Avity Investment Management Inc. reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 16.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,205 shares of the medical research company's stock after selling 7,559 shares during the period. Avity Investment Management Inc.'s holdings in Thermo Fisher Scientific were worth $15,896,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of TMO. Atwood & Palmer Inc. increased its holdings in shares of Thermo Fisher Scientific by 0.5% during the 2nd quarter. Atwood & Palmer Inc. now owns 54,062 shares of the medical research company's stock worth $21,920,000 after buying an additional 274 shares during the last quarter. Granite Bay Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 33.1% in the second quarter. Granite Bay Wealth Management LLC now owns 13,667 shares of the medical research company's stock valued at $5,541,000 after acquiring an additional 3,395 shares during the last quarter. RMR Wealth Builders increased its stake in Thermo Fisher Scientific by 24.6% during the second quarter. RMR Wealth Builders now owns 3,574 shares of the medical research company's stock worth $1,449,000 after acquiring an additional 705 shares during the last quarter. NBC Securities Inc. raised its position in Thermo Fisher Scientific by 9.4% in the second quarter. NBC Securities Inc. now owns 2,741 shares of the medical research company's stock valued at $1,111,000 after purchasing an additional 235 shares during the period. Finally, Apella Capital LLC grew its holdings in shares of Thermo Fisher Scientific by 6.7% during the 2nd quarter. Apella Capital LLC now owns 640 shares of the medical research company's stock worth $268,000 after purchasing an additional 40 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 1.3%

Shares of NYSE:TMO traded up $6.24 during trading on Tuesday, hitting $480.70. The company's stock had a trading volume of 1,799,780 shares, compared to its average volume of 1,482,249. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The business has a 50 day moving average price of $469.07 and a two-hundred day moving average price of $450.41. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market capitalization of $181.52 billion, a PE ratio of 27.80, a P/E/G ratio of 2.53 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the business posted $5.37 earnings per share. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 in the last 90 days. Corporate insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

TMO has been the topic of a number of recent analyst reports. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research report on Friday, July 11th. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. Finally, Barclays raised Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $490.00 to $550.00 in a research note on Thursday, September 11th. Seventeen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $592.24.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.